← Leaderboards
Dwight D Koeberl
Duke University
$10,403,079
Attributed
$11,281,039
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,881,039 · 9
FDA$400,000 · 1
By mechanism
R01$9,319,583 · 6
U01$1,162,179 · 1
R21$373,173 · 1
U34$266,902 · 1
R56$159,202 · 1
Top collaborators
- Nenad Bursac6 shared
Most similar at Duke University
Same institution · by research overlap
- Priya S. Kishnani$1,826,678
- Yuan T Chen$792,683
- Nenad Bursac$22,509,345
- Priya S Kishnani$685,042
- Vandana Shashi$14,579,906
Others in their field
Top investigators on “Glycogen”
- Matthew S. Gentry · University Of Florida$16,983,838
- Peter J Roach · Indiana Univ-Purdue Univ At Indianapolis$14,912,461
- Peter S Klein · University Of Pennsylvania$10,135,315
- Richard S Jope · University Of Alabama At Birmingham$9,093,701
- Alan D Cherrington · Vanderbilt University$8,845,730
- David H Perlmutter · Washington University$8,796,369
Research focus
GlycogenGene TherapyGlycogen Storage Disease Type IiAcidsEnzyme Replacement TherapyVectorGlucan 1,4-Alpha-GlucosidaseGlucosidaseMuscleAdeno-Associated Viral VectorInfancyLiverMuscle WeaknessIn VivoHeartRecombinantsMediatingPreventIn VitroBaseMyopathyCellsAntibodiesImmune Response
Grant awards (32)
Stable therapy in Pompe disease through genome editing$575,718
R01 · FY2025 · AR · contact PI
Stable therapy in Pompe disease through genome editing$674,510
R01 · FY2024 · AR · contact PI
Stable therapy in Pompe disease through genome editing$664,226
R01 · FY2023 · AR · contact PI
Stable therapy in Pompe disease through genome editing$642,427
R01 · FY2022 · AR · contact PI
Stable therapy in Pompe disease through genome editing$717,332
R01 · FY2021 · AR · contact PI
Genome editing for the correction of Pompe disease$201,084
R21 · FY2021 · AR · contact PI
Genome editing for the correction of Pompe disease$172,089
R21 · FY2020 · AR · contact PI
Investigating Autophagy in GSD-Ia$159,202
R56 · FY2020 · DK · contact PI
Investigating Autophagy in GSD-Ia$320,742
R01 · FY2019 · DK · contact PI
A Phase I Study of the Safety of AAV2/8 LSPhGAA in Late-onset Pompe Disease$791,218
U01 · FY2018 · AR · contact PI
Investigating Autophagy in GSD-Ia$320,889
R01 · FY2018 · DK · contact PI
A Phase I Study of the Safety of AAV2/8 LSPhGAA in Late-onset Pompe Disease$370,961
U01 · FY2017 · AR · contact PI
Translational studies of GAA deficiency in bioengineered human muscle$330,989
R01 · FY2017 · AR
Investigating Autophagy in GSD-Ia$321,034
R01 · FY2017 · DK · contact PI
Investigating Autophagy in GSD-Ia$334,450
R01 · FY2016 · DK · contact PI
Translational studies of GAA deficiency in bioengineered human muscle$331,090
R01 · FY2016 · AR
Translational studies of GAA deficiency in bioengineered human muscle$331,188
R01 · FY2015 · AR
Translational studies of GAA deficiency in bioengineered human muscle$100,000
R01 · FY2015 · AR
Translational studies of GAA deficiency in bioengineered human muscle$331,282
R01 · FY2014 · AR
Phase 1/2 Study of Clenbuterol for the Treatment of Pompe Disease$200,000
R01 · FY2014 · FD · contact PI
Translational studies of GAA deficiency in bioengineered human muscle$331,372
R01 · FY2013 · AR
Clinical Trial Planning in Pompe Disease$266,902
U34 · FY2013 · AR · contact PI
Phase 1/2 Study of Clenbuterol for the Treatment of Pompe Disease$200,000
R01 · FY2013 · FD · contact PI
Mechanisms for immune tolerance in Pompe Disease$459,578
R01 · FY2010 · HD · contact PI
Gene delivery to striated muscle by systemic AAV vectors$302,952
R01 · FY2010 · HL · contact PI
Gene delivery to striated muscle by systemic AAV vectors$121,843
R01 · FY2010 · HL · contact PI
Mechanisms for immune tolerance in Pompe Disease$456,800
R01 · FY2009 · HD · contact PI
Gene delivery to striated muscle by systemic AAV vectors$318,770
R01 · FY2009 · HL · contact PI
Gene delivery to striated muscle by systemic AAV vectors$302,952
R01 · FY2008 · HL · contact PI
Gene delivery to striated muscle by systemic AAV vectors$15,403
R01 · FY2008 · HL · contact PI
Gene delivery to striated muscle by systemic AAV vectors$302,952
R01 · FY2007 · HL · contact PI
Gene delivery to striated muscle by systemic AAV vectors$311,084
R01 · FY2006 · HL · contact PI